MannKind Corp. MNKD was a big mover last session, as the company saw its shares surge a whopping 73.9% on the day. This tremendous rally can be attributable to solid volume too with far more shares changing hands than in a normal session. This broke the recent trend of the company, as the stock is now trading above the volatile price range of $4.02 to $6.08 in the past one-month time frame. The share price appreciated when the advisory panel of the U.S. Food and Drug Administration (FDA) voted in favor of the approval of the company's diabetes candidate, Afrezza.
In the last 30 days, the company witnessed 2 downward estimate revisions and the Zacks Consensus Estimate of a loss widened, suggesting there may be trouble down the road. So make sure to keep an eye on this stock going forward to see if this high can last.
MannKind Corp currently has a Zacks Rank #4 (Sell) while its Earnings ESP is positive.
Some better-ranked stocks in the healthcare industry include Alexion Pharmaceuticals, Inc. ALXN, ANI Pharmaceuticals, Inc. ANIP and Aastrom Biosciences, Inc. ASTM all carrying a Zacks Rank #1 (Strong Buy)
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>
ALEXION PHARMA ALXN: Free Stock Analysis Report
ANI PHARMACEUT ANIP: Free Stock Analysis Report
AASTROM BIOSCI ASTM: Get Free Report
MANNKIND CORP MNKD: Free Stock Analysis Report
To read this article on Zacks.com click here.
Zacks Investment Research
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
